Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2009 Apr 26;64(3):629–633. doi: 10.1007/s00280-009-1004-y

Fig. 1. STI571 inhibits cell growth, proliferation, and induces apoptosis of cells containing highly active Abl kinases.

Fig. 1

(a) MDA-MB-435s melanoma cells and MDAMB-468 breast cancer cells were plated in serum in triplicate 6-well dishes, STI571 was added the next day (Day 2), and cell growth was assessed by counting trypan blue-negative cells on a hemacytometer. Experiments shown are representative of three independent experiments. (b) Cell lines were plated in triplicate in 12-well dishes, the media was replaced the next day with media containing STI571, and tritiated thymidine incorporation was measured 72 hours later. Experiments shown are mean ± s.e.m. of three independent experiments. Values were normalized to values obtained in untreated wells and expressed as a percentage of untreated. *p<0.05, ***p<0.001 using Student t-tests. (c) Cells were plated in 6-well dishes, the media was replaced with media containing STI571 the next day, and caspase-3/7 activity was detected in detached and attached cells by fluorescent caspase assay, 40 hours after treatment. Mean ± s.e.m. of three independent experiments. ***p<0.001 using a Student t-test. Fig. 1a was adapted from Srinivasan and Plattner (2006) [7].